Emergent BioSolutions (EBS) said Wednesday that the US Department of Defense has exercised a contract option to buy around $20 million of the company's BioThrax anthrax vaccine.
In December, the company shipped about $7 million of the pre-exposure vaccine to the Pentagon for distribution among all six branches of the US military, with the remaining deliveries expected over the rest of 2025, it said.
The purchase was authorized through the company's existing procurement contract with the Defense Department and its Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.
Emergent last month also disclosed a $50 million contract option to supply up to $50 million of its Cyfendus anthrax vaccine to the federal government expected to be completed by April.
Price: 9.99, Change: -0.29, Percent Change: -2.80
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。